title: Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.
abstract: OBJECTIVE
  Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest.
  
  
  METHODS
  This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens.
  
  
  RESULTS
  Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity.
  
  
  CONCLUSIONS
  These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.forename: Pilar
authors.initials: P
authors.lastname: Giraldo
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kotsianidis
authors.forename: Catherine
authors.initials: C
authors.lastname: Couturier
authors.forename: Robert
authors.initials: R
authors.lastname: Olie
authors.forename: Ralf
authors.initials: R
authors.lastname: Angermund
authors.forename: Alessandro
authors.initials: A
authors.lastname: Corso
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000069286:Bortezomib / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D000069286:Bortezomib
keywords: Bortezomib; Efficacy; Multiple myeloma; Retreatment; Safety